In the "Euroflow standardization of flow cytometer instruments settings and immunophenotyping protocols" (Kalina et al., 2012), nothing is detailed concerning viability. The ISHAGE protocol lets think that we should perform a viability measurement on each tube of the panel. What do you think about that point?
The importance or relevance of measuring viability depends somewhat on the tissue source of your haematopoietic stem cell (HSC) samples (bone marrow, cord blood, peripheral blood apheresis) and the handling/storage conditions. If the samples are tested soon after HSC collection and processing, then viability is likely to be very high. However, if there is a time delay between HSC collection and processing (and testing) (i.e. more than 24 hours) then including viability measurement would be a good idea.
I envisage to use a viability marker such as 7-AAD. But compensations are so huge to use it in a normal antibody panel, so I wont respect Euroflow protocol!
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Cell Biology
- Culture Cells
- Cell Line